Hypertrophic Obesity and Subcutaneous Adipose Tissue Dysfunction
Abstract
BACKGROUND: Over the past 50 years, scientists have recognized that not all adipose tissue is alike, and that health risk is associated with the location as well as the amount of body fat. Different depots are sufficiently distinct with respect to fatty-acid storage and release as to probably play unique roles in human physiology. Whether fat redistribution causes metabolic disease or whether it is a marker of underlying processes that are primarily responsible is an open question.
CONTENT: The limited expandability of the subcutaneous adipose tissue leads to inappropriate adipose cell expansion (hypertrophic obesity) with local inflammation and a dysregulated and insulin-resistant adipose tissue. The inability to store excess fat in the subcutaneous adipose tissue is a likely key mechanism for promoting ectopic fat accumulation in tissues and areas where fat can be stored, including the intra-abdominal and visceral areas, in the liver, epi/pericardial area, around vessels, in the myocardium, and in the skeletal muscles. Many studies have implicated ectopic fat accumulation and the associated lipotoxicity as the major determinant of the metabolic complications of obesity driving systemic insulin resistance, inflammation, hepatic glucose production, and dyslipidemia.
SUMMARY: In summary, hypertrophic obesity is due to an impaired ability to recruit and differentiate available adipose precursor cells in the subcutaneous adipose tissue. Thus, the subcutaneous adipose tissue may be particular in its limited ability in certain individuals to undergo adipogenesis during weight increase. Inability to promote subcutaneous adipogenesis under periods of affluence would favor lipid overlow and ectopic fat accumulation with negative metabolic consequences.
KEYWORDS: obesity, adipogenesis, subcutaneous adipose tissue, visceral adipose tissue, adipocyte dysfunction
Full Text:
PDFReferences
Prospective Studies Collaboration. Prospective studies collaboration: body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009; 373: 1083-96, CrossRef.
Krotkiewski M, Björntorp P, Sjöström L, Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest. 1983; 72: 1150-62, CrossRef.
Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006; 444: 881-7, CrossRef.
Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012; 308: 1150-9, CrossRef.
Gustafson B, Hammarstedt A, Hedjazifar S, Smith U. Restricted adipogenesis in hypertrophic obesity. The role of WISP2, WNT, and BMP4. Diabetes. 2013; 62: 2997-3004, CrossRef.
Kirkland JL, Hollenberg CH, Gillon WS. Age, anatomic site, and the replication and differentiation of adipocyte precursors. Am J Physiol. 1990; 258: C206-10, PMID.
Tchkonia T, Corkey BE, Kirkland JL. Current views of the fat cell as an endocrine cell: lipotoxicity, vol. 26. In: Bray GA, Ryan DH, editors. Endocrine Updates: Overweight and the Metabolic Syndrome. New York: Springer; 2006. p.105-23, CrossRef.
Thomou T, Tchkonia T, Kirkland JL. Cellular and molecular basis of functional differences among fat depots. In: Leff TA, Granneman JG, editors. Adipose Tissue in Health and Disease. Weinheim: Wiley; 2010. p.21-47, CrossRef.
Mauer MM, Harris RB, Bartness TJ. The regulation of total body fat: lessons learned from lipectomy studies. Neurosci Biobehav Rev. 2001; 25: 15-28, CrossRef.
Tchkonia T, Thomou T, Zhu Y, Keragiannides I, Pothoulakis C, Jensen D, et al. Mechanisms and metabolic implications of regional differences among fat depots. Cell Metab. 2013; 17: 644-56, CrossRef.
Frayn K. Adipose tissue as a buffer for daily lipid flux. Diabetologia. 2002; 45: 1201-10, CrossRef.
Bjørndal B, Burri L, Staalesen V, Skorve J, Berge RK. Different adipose depots: their role in the development of metabolic syndrome and mitochondrial response to hypolipidemic agents. J Obes. 2011; 2011: 490650, CrossRef.
Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev. 2003; 84: 277-359, CrossRef.
Fantuzzi G. Adipose tissue, adipokines, inflammation. J Allergy Clin Immunol. 2005; 115: 911-9, CrossRef.
Iacobellis G, Pistilli D, Gucciardo M, Leonetti F, Miraldi F, BrancaccioG, et al. Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease. Cytokine. 2005; 29: 251-5, CrossRef.
Iacobellis G, Willens HJ. Echocardiographic epicardial fat: a review of research and clinical applications. J Am Soc Echocardiogr. 2009; 22: 1311-9, CrossRef.
Ouwens DM, Sell H, Greulich S, Eckel J. The role of epicardial and perivascular adipose tissue in the pathophysiology of cardiovascular disease. J Cell Mol Med. 2010; 14: 2223-4, CrossRef.
Iozzo P. Myocardial, perivascular, and epicardial fat. Diabetes Care. 2011; 34 Suppl 2: S371-9, CrossRef.
Yudkin JS, Eringa E, Stehouwer CDA. Vasocrine signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet. 2005; 365: 1817-20, CrossRef.
Fazeli PK, Horowitz MC, MacDougald OA, Scheller EL, Rodeheffer MS, Rosen CJ, et al. Marrow fat and bone - New perspectives. J Clin Endocrinol Metab. 2013; 98: 935-45, CrossRef.
Tchoukalova YD, Votruba SB, Tchkonia T, Giorgadze N, Kirkland JL, Jensen MD. Regional differences in cellular mechanisms of adipose tissue gain with overfeeding. Proc Natl Acad Sci USA. 2010; 107, 18226-31, CrossRef.
Tchkonia T, Morbeck DE, Von Zglinicki T, Van Deursen J, Lustgarten J, Scrable H, et al. Fat tissue, aging, and cellular senescence. Aging Cell. 2010; 9: 667-84, CrossRef.
Cawthorn W, Scheller E, MacDougald OA. Adipose tissue stem cells meet preadipocyte commitment: going back to the future. J Lipid Res. 2012; 53: 227-42, CrossRef.
Hellman B, Hellerstrom C. Cell renewal in the white and brown fat tissue of the rat. Acta Pathol Microbiol Scand. 1961; 51: 347-53, CrossRef.
Hirsch J, Han PW. Cellularity of rat adipose tissue: effects of growth, starvation, and obesity. J Lipid Res. 1969; 10: 77-82, PMID.
Lemonnier D. Effect of age, sex, and sites on the cellularity of the adipose tissue in mice and rats rendered obese by a high-fat diet. J Clin Invest. 1972; 51: 2907-15, CrossRef.
Häger A, Sjöstrm L, Arvidsson B, Björntorp P, Smith U. Body fat and adipose tissue cellularity in infants: a longitudinal study. Metabolism. 1977; 26 : 607-14, CrossRef.
Bertrand HA, Masoro EJ, Yu BP. Increasing adipocyte number as the basis for perirenal depot growth in adult rats. Science. 1978; 201: 1234-5, CrossRef.
Faust IM, Johnson PR, Stern JS, Hirsch J. Diet-induced adipocyte number increase in adult rats: a new model of obesity. Am J Physiol. 1978; 235: E279-86, PMID.
Knittle JL, Timmers K, Ginsberg-Fellner F, Brown RE, Katz DP. The growth of adipose tissue in children and adolescents. Crosssectional and longitudinal studies of adipose cell number and size. J Clin Invest. 63: 239-246, CrossRef.
Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann O, et al. Dynamics of fat cell turnover in humans. Nature. 2008; 453: 783-7, CrossRef.
Rigamonti A, Brennand K, Lau F, Cowan CA. Rapid cellular turnover in adipose tissue. PLoS ONE. 2011; 6: e17637, CrossRef.
Prins JB, O’Rahilly S. Regulation of adipose cell number in man. Clin Sci. 1997; 92: 3-11, CrossRef.
Garaulet M, Hernandez-Morante JJ, Lujan J, Tebar FJ, Zamora S. Relationship between fat cell size and number and fatty acid composition in adipose tissue from different fat depots in overweight obese humans. Int J Obes. 2006; 6: 899-905, CrossRef.
Hausman DB, DiGirolamo M, Bartness TJ, Hausman GJ, Martin RJ. The biology of white adipocyte proliferation. Obesity Rev. 2001; 2: 239-54, CrossRef.
Gregoire F. Adipocyte differentiation: from fibroblast to endocrine cell. Exp Biol Med. 2001; 226: 997-1002, PMID.
Fajas L. Adipogenesis: a cross-talk between cell proliferation and cell differentiation. Ann Med. 2003; 35: 79-85, CrossRef.
Smas CM, Sul HS. Control of adipocyte differentiation. Biochem J. 1995; 309: 697-710, CrossRef.
Ailhaud G, Grimaldi P, Negrel R. Cellular and molecular aspects of adipose tissue development. Annu Rev Nutr. 1992; 12: 207-33, CrossRef.
Rodbell M. Metabolism of isolated fat cells. I. Effects of hormones on glucose metabolism and lipolysis. J Biol Chem. 1964; 239: 375-80, CrossRef.
Ng CW, Poznanski WJ, Borowiecki M, Reimer G. Differences in growth in vitro of adipose cells from normal and obese patients. Nature. 1971; 231: 445, CrossRef.
Poznanski WJ, Waheed I, Van R. Human fat cell precursors. Morphologic and metabolic differentiation in culture. Lab Invest. 1973; 29: 570-6, PMID.
Van RL, Bayliss CE, Roncari DA. Cytological and enzymological characterization of adult human adipocyte precursors in culture. J Clin Invest. 1976; 58 : 699-704, CrossRef.
Farmer SR. Transcriptional control of adipocyte formation. Cell Metab. 2006; 4: 263-73, CrossRef.
Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol. 2006; 7: 885-96, CrossRef.
Christodoulides C, Lagathu C, Sethi JK, Vidal-Puig A. Adipogenesis and WNT signalling. Trends Endocrinol Metab. 2009; 20: 16-24, CrossRef.
Lefterova MI, Lazar MA. New developments in adipogenesis. Trends Endocrinol Metab. 2009; 20: 107-14, CrossRef.
Lowe CE, O'Rahilly S, Rochford JJ. Adipogenesis at a glance. J Cell Sci. 2011; 124: 2681-6, CrossRef.
Eguchi J, Yan QW, Schones DE, Kamal M, Hsu CH, Zhang MQ, et al. Interferon regulatory factors are transcriptional regulators of adipogenesis. Cell Metab. 2008; 7: 86-94, CrossRef.
Nielsen R, Pedersen TA, Hagenbeek D, Moulos P, Siersbaek R, Megens E, et al. Genome-wide profi ling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. Genes Dev. 2008; 22: 2953-67, CrossRef.
Steger DJ, Grant GR, Schupp M, Tomaru T, Lefterova MI, Schug J, et al. Propagation of adipogenic signals through an epigenomic transition state. Genes Dev. 2010; 24: 1035-44, CrossRef.
Siersbæk R, Nielsen R, John S, Sung MH, Baek S, Loft A, et al. Extensive chromatin remodeling and establishment of transcription factor ‘hotspots’ during early adipogenesis. EMBO J. 2011; 30: 1459-72, CrossRef.
Arner E, Westermark PO, Spalding KL, Britton T, Rydén M, Frisén J, et al. Adipocyte turnover: relevance to human adipose tissue morphology. Diabetes. 2010; 59: 105-9, CrossRef.
Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic b cell dedifferentiation as a mechanism of diabetic b cell failure. Cell. 2012; 150: 1223-34, CrossRef.
Isakson P, Hammarstedt A, Gustafson B, Smith U. Impaired preadipocyte differentiation in human abdominal obesity: role of Wnt, tumor necrosis factor-alpha, and inflammation. Diabetes. 2009; 58: 1550-7, CrossRef.
Clevers H, Nusse R. Wnt/b-catenin signaling and disease. Cell. 2012; 149: 1192-205, CrossRef.
Wu Z, Rosen ED, Brun R, Hauser S, Adelmant G, Troy AE, et al. Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol Cell. 1999; 3: 151-8, CrossRef.
Gustafson B, Eliasson B, Smith U. Thiazolidinediones increase the winglesstype MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link with osteogenesis. Diabetologia. 2010; 53: 536-40, CrossRef.
Gustafson B, Smith U. The WNT inhibitor Dickkopf 1 and bone morphogenetic protein 4 rescue adipogenesis in hypertrophic obesity in humans. Diabetes. 2012; 61: 1217-24, CrossRef.
Bowers RR, Kim JW, Otto TC, Lane MD. Stable stem cell commitment to the adipocyte lineage by inhibition of DNA methylation: role of the BMP-4 gene. Proc Natl Acad Sci USA. 2006; 103: 13022-7, CrossRef.
Tseng YH, Kokkotou E, Schulz TJ, Huang TL, Winnay JN, Taniguchi CM, et al. New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. Nature. 2008; 454: 1000-4, CrossRef.
Camp HS, Ren D, Leff T. Adipogenesis and fat-cell function in obesity and diabetes. Trends Mol Med. 2002; 8: 442-7, CrossRef.
Sethi JK. Obesity: adipogenesis and insulin resistance. IDrugs. 2000; 3: 884-6, PMID.
Zeyda M, Stulnig TM. Obesity, inflammation, and insulin resistance - A mini-review. Gerontology. 2009; 55: 379-86, CrossRef.
Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006; 444: 860-7, CrossRef.
Andersson CX, Gustafson B, Hammarstedt A, Hedjazifar S, Smith U. Inflamed adipose tissue, insulin resistance and vascular injury. Diabetes Metab Res Rev. 2008; 24: 595-603, CrossRef.
Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2007; 27: 2276-83, CrossRef.
Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. 2010; 314: 1-16, CrossRef.
Arner P, Arner E, Hammarstedt A, Smith U. Genetic predisposition for type 2 diabetes, but not for overweight/obesity, is associated with a restricted adipogenesis. PLoS One. 2011; 6: e18284, CrossRef.
Jansson PA, Pellmé F, Hammarstedt A, Sandqvist M, Brekke H, Caidahl K, et al. A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin. FASEB J. 2003; 17: 1434-40, CrossRef.
Rondinone CM, Wang LM, Lonnroth P, Wesslau C, Pierce JH, Smith U. Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA. 1997; 94: 4171-5, CrossRef.
Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest. 2007; 117: 2621-37, CrossRef.
Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112: 1796-808, CrossRef.
McQuaid SE, Hodson L, Neville MJ, Dennis AL, Cheeseman J, Humphreys SM, et al. Downregulation of adipose tissue fatty acid trafficking in obesity: a driver for ectopic fat deposition? Diabetes. 2011; 60: 47-55, CrossRef.
Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res. 2005; 46: 2347-55, CrossRef.
Fischer-Posovszky P, Wang QA, Asterholm IW, Rutkowski JM, Scherer PE. Targeted deletion of adipocytes by apoptosis leads to adipose tissue recruitment of alternatively activated M2 macrophages. Endocrinology. 2011; 152: 3074-81, CrossRef.
Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest. 1998; 101: 1354-61, CrossRef.
Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012; 142: 711-25, CrossRef.
Denis GV, Obin MS. “Metabolically healthy obesity”: origins and implications. Mol Aspects Med. 2013; 34: 59-70, CrossRef.
Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. Global burden of metabolic risk factors of chronic diseases collaborating group (body mass index). National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet. 2011; 377: 557-67, CrossRef.
Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA. 2004; 291: 2847-50, CrossRef.
Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006; 355: 763-78, CrossRef.
Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Diabetes Care. 2006; 29: 1697-9, CrossRef.
Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world - A growing challenge. N Engl J Med. 2007; 356: 213-5, CrossRef.
Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. J Clin Invest. 1997; 100: 1166-73, CrossRef.
Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998; 47: 1643-9, CrossRef.
Brochu M, Tchernof A, Dionne IJ, Sites CK, Eltabbakh GH, Sims EA, et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J Clin Endocrinol Metab. 2001; 86: 1020-5, CrossRef.
Sims EA. Are there persons who are obese, but metabolically healthy? Metabolism. 2001; 50: 1499-504, CrossRef.
Karelis AD, Brochu M, Rabasa-Lhoret R. Can we identify metabolically healthy but obese individuals (MHO)? Diabetes Metab. 2004; 30: 569-72, CrossRef.
Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, Sullivan LM, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006; 91: 2906-12, CrossRef.
Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med. 2008; 168: 1617-24, CrossRef.
Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008; 168: 1609-16, CrossRef.
Karelis AD. Metabolically healthy but obese individuals. Lancet. 2008; 372: 1281-3, CrossRef.
Messier V, Karelis AD, Prud’homme D, Primeau V, Brochu M, Rabasa-Lhoret R. Identifying metabolically healthy but obese individuals in sedentary postmenopausal women. Obesity. 2010; 18: 911-7, CrossRef.
Primeau V, Coderre L, Karelis AD, Brochu M, Lavoie ME, Messier V, et al. Characterizing the profile of obese patients who are metabolically healthy. Int J Obes. 2011; 35: 971-81, CrossRef.
Klöting N, Fasshauer M, Dietrich A, Kovacs P, Schön MR, Kern M, et al. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab. 2010; 299: E506-15, CrossRef.
Spencer M, Yao-Borengasser A, Unal R, Rasouli N, Gurley CM, Zhu B, et al. Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation. Am J Physiol Endocrinol Metab. 2010; 299: E1016-27, CrossRef.
Pasarica M, Gowronska-Kozak B, Burk D, Remedios I, Hymel D, Gimble J, et al. Adipose tissue collagen VI in obesity. J Clin Endocrinol Metab. 2009; 94: 5155-62, CrossRef.
Huang Y, Yan X, Zhu MJ, McCormick RJ, Ford SP, Nathanielsz PW, et al. Enhanced transforming growth factor-beta signaling and fibrogenesis in ovine fetal skeletal muscle of obese dams at late gestation. Am J Physiol Endocrinol Metab. 2010; 298: E1254-60, CrossRef.
Dubois SG, Heilbronn LK, Smith SR, Albu JB, Kelley DE, Ravussin E. Decreased expression of adipogenic genes in obese subjects with type 2 diabetes. Obesity. 2006; 14: 1543-52, CrossRef.
Trayhurn P, Wang B, Wood IS. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br J Nutr. 2008; 100: 227-35, CrossRef.
Chun TH, Hotary KB, Sabeh F, Saltiel AR, Allen ED, Weiss SJ. A pericellular collagenase directs the 3-dimensional development of white adipose tissue. Cell. 2006; 125: 577-91, CrossRef.
Henegar C, Tordjman J, Achard V, Lacasa D, Cremer I, Guerre-Millo M, et al. Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesity. Genome Biol. 2008; 9: R14, CrossRef.
Halberg N, Khan T, Trujillo ME, Wernstedt-Asterholm I, Attie AD, Sherwani S, et al. Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue. Mol Cell Biol. 2009; 29: 4467-83, CrossRef.
Khan T, Muise ES, Iyengar P, Wang ZV, Chandalia M, Abate N, et al. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol Cell Biol. 2009; 29: 1575-91, CrossRef.
Divoux A, Tordjman J, Lacasa D, Veyrie N, Hugol D, Aissat A, et al. Fibrosis in human adipose tissue: composition, distribution, and link with lipid metabolism and fat mass loss. Diabetes. 2010; 59: 2817-25, CrossRef.
Shaul ME, Bennett G, Strissel KJ, Greenberg AS, Obin MS. Dynamic, M2-like remodeling phenotypes of CD11c+ adipose tissue macrophages during high fat diet-induced obesity in mice. Diabetes. 2010; 59: 1171-81, CrossRef.
Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell. 2010; 140: 900-17, CrossRef.
Deng J, Lu PD, Zhang Y, Scheuner D, Kaufman RJ, Sonenberg N, et al. Translational repression mediates activation of nuclear factor kappa B by phosphorylated translation initiation factor 2. Mol Cell Biol. 2004; 24: 10161-8, CrossRef.
Hu P, Han Z, Couvillon AD, Kaufman RJ, Exton JH. Autocrine tumor necrosis factor alpha links endoplasmic reticulum stress to the membrane death receptor pathway through IRE1alpha-mediated NFkappaB activation and down-regulation of TRAF2 expression. Mol Cell Biol. 2006; 26: 3071-84, CrossRef.
Cullinan SB, Diehl JA. Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway. Int J Biochem Cell Biol. 2006; 38: 317-32, CrossRef.
Gotoh T, Mori M. Nitric oxide and endoplasmic reticulum stress. Arterioscler Thromb Vasc Biol. 2006; 26: 1439-46, CrossRef.
Ota T. Chemokine system link obesity to insulin resistance. Diabetes Metab J. 2013; 37: 165-72, CrossRef.
Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004; 25: 677-86, CrossRef.
Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007; 117: 175-84, CrossRef.
Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature. 2007; 447: 1116-20, CrossRef.
Patsouris D, Li PP, Thapar D, Chapman J, Olefsky JM, Neels JG. Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab. 2008; 8: 301-9, CrossRef.
Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, et al. GPR120 is an omega-3 fatty acid receptor mediating potent antiinflammatory and insulin-sensitizing effects. Cell. 2010; 142: 687-98, CrossRef.
Bouhlel MA, Derudas B, Rigamonti E, Dièvart R, Brozek J, Haulon S, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007; 6: 137-143, CrossRef.
Chawla A, Nguyen KD, Goh YP. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol. 2011; 11: 738-49, CrossRef.
Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005; 365: 1415-28, CrossRef.
Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr Rev. 2008; 29: 777-822, CrossRef.
Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm. 2010; 2010: 289645, CrossRef.
Després JP, Lemieux S, Lamarche B, Prud'homme D, Moorjani S, Brun LD, et al. The insulin resistance dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications. Int J Obes Relat Metab Disord. 1995; 19 Suppl 1: S76-86, PMID.
Després JP. Is visceral obesity the cause of the metabolic syndrome? Ann Med. 2006; 38: 52-63, CrossRef.
Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, et al. Abdominal visceral and subcutaneous adipose framingham heart study. Circulation. 2007; 116: 39-48, CrossRef.
Porter SA, Massaro JM, Hoffmann U, Vasan RS, O'Donnel CJ, Fox CS. Abdominal subcutaneous adipose tissue: a protective fat depot? Diabetes Care. 2009; 32: 1068-75, CrossRef.
Goodpaster BH, Thaete FL, Simoneau JA, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes. 1997; 46: 1579-85, CrossRef.
Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest. 1995; 96: 88-98, CrossRef.
Abate N, Garg A, Peshock RM, Stray-Gundersen J, Adams-Huet B, Grundy SM. Relationship of generalized and regional adiposity to insulin sensitivity in men with NIDDM. Diabetes. 1996; 45: 1684-93, CrossRef.
Ferreira I, Henry RM, Twisk JW, van Mechelen W, Kemper HC, Stehouwer CD, et al. The metabolic syndrome, cardiopulmonary fitness, and subcutaneous trunk fat as independent determinants of arterial stiffness: the Amsterdam Growth and Health Longitudinal Study. Arch Intern Med. 2005; 165: 875-82, CrossRef.
Salmenniemi U, Ruotsalainen E, Pihlajamäki J, Vauhkonen I, Kainulainen S, Punnonen K, et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation. 2004; 110: 3842-8, CrossRef.
Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, et al. Intra abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for themetabolic syndrome. Diabetes. 2004; 53: 2087-94, CrossRef.
Apovian CM, Bigornia S, Mott M, Meyers MR, Ulloor J, Gagua M, et al. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol. 2008; 28: 1654-9, CrossRef.
Bremer AA, Jialal I. Adipose tissue dysfunction in nascent metabolic syndrome. J Obes. 2013; 2013: 393192, CrossRef.
Jialal I, Devaraj S, Adams-Huet B, Chen X, Kaur H. Increased cellular and circulating biomarkers of oxidative stress in nascent metabolic syndrome. J Clin Endocrinol Metab. 2012; 97: E1844-50, CrossRef.
Ernst MC, Sinal CJ. Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab. 2010; 21: 660-7, CrossRef.
Bozaoglu K, Segal D, Shields KA, Cummings N, Curran JE, Comuzzie AG, et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab. 2009; 94: 3085-8, CrossRef.
Sell H, Divoux A, Poitou C, Basdevant A, Bouillot JL, Bedossa P, et al. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metab. 2010; 95: 2892-6, CrossRef.
Sell H, Laurencikiene J, Taube A, Eckardt K, Cramer A, Horrighs A, et al. Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes. 2009; 58: 2731-40, CrossRef.
Schäffler A, Neumeier M, Herfarth H, Fürst A, Schölmerich J, Büchler C. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta. 2005; 1732: 96-102, CrossRef.
Tan BK, Adya R, Randeva HS. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med. 2010; 20: 143-8, CrossRef.
de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007; 56: 1655-61, CrossRef.
DOI: https://doi.org/10.18585/inabj.v6i2.33
Copyright (c) 2014 The Prodia Education and Research Institute

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:





The Prodia Education and Research Institute